PathAI

PathAI is a leading AI-powered pathology company that has developed a comprehensive platform, AISight®, for digital pathology image management and AI algorithm deployment. It serves two primary markets: biopharma clients, for whom it provides translational research, clinical trial services, and diagnostic development, and anatomic pathology laboratories, which use its platform for workflow digitization and AI-assisted diagnostics. The company has achieved significant regulatory milestones, including FDA clearance for its AISight® Dx platform for primary diagnosis and FDA qualification for its AIM-MASH tool for clinical trials, and collaborates with major industry players like Labcorp and top biopharma firms.

AISight®: A cloud-native digital pathology platform comprising an Image Management System (IMS) and an FDA-cleared diagnostic module (AISight® Dx). It serves as a central hub for case/image management and deployment of proprietary and third-party AI algorithms for tissue analysis.

PathAI competes in a rapidly evolving landscape including pure-play AI pathology startups (e.g., Paige, Proscia), large diagnostic companies developing digital solutions (e.g., Roche, Philips), and biopharma-focused image analysis firms (e.g., Visiopharm). Its differentiation lies in its full-stack platform (AISight®), extensive pathologist network for algorithm training, and proven commercial traction with top biopharma and major labs like Labcorp.